Hematology Frontier

The 66th Annual Meeting of the American Society of Hematology (ASH), the largest and most comprehensive international conference in hematology, successfully took place from December 7 to 10, 2024, in San Diego, USA. This annual event attracts numerous hematology experts and scholars worldwide to exchange ideas and discuss significant breakthroughs in the field. During this year's ASH conference, the Chinese American Hematologist and Oncologist Network (CAHON) held its 2024 Winter Symposium. Experts shared insights, reviewed past accomplishments, and presented cutting-edge advancements in areas ranging from basic research to clinical applications. The event not only fostered academic exchanges and knowledge sharing but also played a pivotal role in advancing the diagnosis and treatment of related diseases while promoting global professional collaboration.

The 66th Annual Meeting of the American Society of Hematology (ASH) successfully concluded in San Diego, USA, from December 7–10, 2024. As the largest and most comprehensive international academic conference in the field of hematology, it attracts global experts and scholars each year to discuss and exchange views on the latest research advancements. During this year’s ASH meeting, the Chinese American Hematologist and Oncologist Network (CAHON) successfully held its Winter Symposium. Hematology frontier invited Dr. JingZhou Hou, CAHON President and a professor at the University of Pittsburgh Medical Center, to share insights on CAHON’s founding mission, highlights from this Winter Symposium, and details of his three research studies (including one oral presentation and two posters) presented at ASH.

The 2024 American Society of Hematology (ASH) Annual Meeting took place in San Diego from December 7 to 10, attracting the global hematology community's attention. As one of the most prestigious international events in the field, this conference has drawn keen interest from researchers and clinicians worldwide, including those in China. To provide timely updates on the most significant daily highlights, Oncology Frontier – Hematology Frontier launched the special column ASH Daily News Highlights. Hosted by Dr. Jun Zhu from Peking University Cancer Hospital, the column features daily expert interviews, offering firsthand insights into the conference. We were honored to connect with Dr. Huiqiang Huang from the Lymphoma Center of Sun Yat-sen University Cancer Hospital to discuss the latest research in lymphoma presented at the conference.

The 66th American Society of Hematology (ASH) Annual Meeting was held in San Diego, USA, from December 7–10, 2024. Renowned as the largest and most comprehensive international academic event in the field of hematology, the conference gathers leading experts and researchers worldwide to discuss and exchange groundbreaking advancements in hematology. At this year's meeting, the research led by Dr. Jing Pan from Beijing GoBroad Boren Hospital garnered significant attention, with two studies related to CAR-T therapy (abstracts 964 and 3466) being featured. To provide a deeper understanding of these pivotal findings, Hematology Frontier interviewed Dr. Jing Pan, who shared insights on these studies and the broader topic of CAR-T therapy. Below is a summary of the research and interview.

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, remains the largest and most comprehensive international academic gathering in the field of hematology. Every year, it draws leading experts and scholars from across the globe for in-depth discussions and exchanges on groundbreaking research. This year, the lymphoma field witnessed several pivotal study outcomes. Oncology Frontier - Hematology Frontier invited Dr. Jun Shi from The Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, to provide a detailed analysis and commentary on two highly impactful studies presented during the meeting.

Myelodysplastic syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, ineffective hematopoiesis, refractory cytopenia, and a potential progression to acute myeloid leukemia (AML). At the 2024 Annual Meeting of the American Society of Hematology (ASH), held from December 7 to 10 in San Diego, numerous studies on MDS were presented, showcasing significant progress in the treatment and prognostic evaluation of low-risk MDS. Oncology Frontier - Hematology Frontier invited Dr. Huaquan Wang from Tianjin Medical University General Hospital to provide expert commentary on the most impactful research in this field, delivering cutting-edge insights to our readers.

The 2024 American Society of Hematology (ASH) Annual Meeting, held from December 7 to 10 in San Diego, continues to be a global focal point for clinicians and researchers in hematology. As one of the most prestigious international conferences in the field, it has captured widespread attention both globally and within China. To provide timely updates on the most significant developments at the conference, Oncology Frontier - Hematology Frontier launched the "ASH Daily News Highlights" series. Dr. Jun Zhu from Peking University Cancer Hospital serves as the series host, connecting daily with onsite experts to bring firsthand updates. On the third day of the conference, we were honored to hear from Dr. Wenming Chen of Beijing Chaoyang Hospital, who shared insights into key studies in the field of myeloma.

Myelodysplastic Syndromes (MDS) are a group of heterogeneous myeloid clonal disorders originating from hematopoietic stem cells, characterized by dysplastic development of myeloid cells, manifested as ineffective hematopoiesis, refractory cytopenia, and the potential to transform into acute myeloid leukemia (AML). At the 2024 American Society of Hematology (ASH) Annual Meeting held in San Diego, USA from December 7th to 10th, numerous studies in the field of MDS were announced, with significant progress particularly in the treatment and prognosis assessment of low-risk MDS. "Hematology Frontier" specially invited Dr. Huaquan Wang from the Department of Hematology, Tianjin Medical University General Hospital, to select and comment on the key studies, in hopes of bringing cutting-edge information and unique insights to everyone.